

07 Apr 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs first ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 April 2024, including: [Genmab A/S](#) buys into ADCs; [Roivant Sciences](#) set to take on [AbbVie Inc.](#) in uveitis; [Ipsen SA](#) signs first ADC pact; South Korea looks to build biotech momentum; and the end of the road for [Acorda Therapeutics, Inc.](#)

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Genmab Adds To Sector ADC Buying Spree With \\$1.8bn ProfoundBio Acquisition](#)" - Scrip, 3 Apr, 2024.)

(Also see "[Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy](#)" - Scrip, 2 Apr, 2024.)

(Also see "[Ipsen Dives Back Into Dealmaking With First ADC Pact](#)" - Scrip, 2 Apr, 2024.)

(Also see "[Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative](#)" - Scrip, 31 Mar,

2024.)

(Also see "[All Over For Acorda After A Torrid Few Years](#)" - Scrip, 3 Apr, 2024.)

[Click here to explore this interactive content online](#) ✨